Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG: Places Maximum Number of New Shares in Capital Increase with Pre-emptive Rights

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Restructuring & Recapitalisations/Company Information/molecular diagnostic
25.01.2013


Not for distribution in the United States

Berlin, Germany, January 25, 2013 - Today the Executive Board of Epigenomics AG,
Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516), with the
approval of the Supervisory Board, has taken the decision to implement the
capital increase from authorized capital, the details of which were announced on
January 7, 2013, for the maximum number of 3,149,430 new ordinary bearer shares,
generating gross proceeds of EUR 4,976,099. 

2,811,707 new ordinary bearer shares were taken up by the shareholders at a
subscription price of EUR 1.58 per new share during the subscription period
which started on January 11, 2013 and ended on January 24, 2013. The remaining
337,723 unsubscribed new shares were sold at the subscription price of EUR 1.58
per new share in a private placement to institutional investors. The private
placement was significantly oversubscribed, enabling Epigenomics AG to place the
maximum number of new shares. The capital increase was conducted by Kempen & Co.

The registration of the implementation of the capital increase with the
commercial register ("Handelsregister") and the admission of the new shares to
the regulated market ("regulierter Markt"), Prime Standard, of the Frankfurt
Stock Exchange are expected on or around January 29, 2013. Trading in the new
shares is expected to begin on January 30, 2013, and delivery of the new shares
to the investors is expected on January 31, 2013. With the registration of the
implementation of the capital increase the total issued share capital of
Epigenomics increases from EUR 8,818,417.00 to EUR 11,967,847.00.

Epigenomics AG intends to use the net proceeds from the share capital increase
to finance its current operations. 

- End of Ad hoc -

Disclaimer

This publication is not an offer of any securities for sale or a solicitation of
an offer to purchase any securities. 
This document is not an offer of securities for sale or a solicitation of an
offer to purchase securities in the United States. The shares of Epigenomics AG
(the "Shares") have not been registered under the U.S. Securities Act of 1933,
as amended (the "Securities Act") and may not be offered or sold in the United
States unless registered under the Securities Act or pursuant to an exemption
from such registration. There will be no public offering of the Shares in the
United States and the Shares will not be registered under the Securities Act. 

Contact:

Epigenomics AG                          
Antje Zeise CIRO
Manager IR | PR 
Epigenomics AG 
Phone: +49 (0) 30 24345 386 
ir@epigenomics.com
www.epigenomics.com


Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: